Bioprocessing & Process Optimization
Sensitively detect subtle differences in CAR-T bioprocessing methods to advance decision making1
Empower decision making in bioprocess optimization by leveraging the power of true functional T cell biology
Identify T cell cytokine production differences with varied bioprocessing methods
IsoPlexis’ systems provide the complete picture
Found consistently more robust, polyfunctional response in modified CAR-T manufacturing protocol
More robust polyfunctional response of CD4+ or CD8+ CAR-T cell products CD19 or CD22 with the modified manufacturing method (MM) compared to the original manufacturing method (OM).
Data demonstrates that the modified CD19/CD22 bispecific CAR-T cell manufacturing method (MM), which terminated T cell activation/transduction by culture day 3, resulted in reproducible and robust CAR-T cell production, even in the relatively more sensitive patient cells.